capital-formation
(8)
Priya Kaftan Works the Room Where Capital Meets Conviction
At Heard Capital, Priya Kaftan translates investment ideas into lasting investor relationships. Beyond the firm, she has helped turn introductions into a practical route for women-led funds seeking institutional capital.
The Tiny Agency Behind $30 Billion of Complicated Money
Spotlight Marketing Communications found a lucrative place between the lawyers and the sales desk: turning regulated investment language into something people can understand, remember and act on.
IRTH Communications and the price of being understood
A stock-market listing gives a company a ticker. IRTH Communications sells the painstaking work that comes next: explaining the business, finding its audience, and keeping the conversation going.
He Shrunk His Agency to Finance a Bigger Idea: Can BlueDot Project Make Regeneration Investable?
Eduardo Esparza left the comfortable agency script for a stranger assignment: make whole communities, watersheds and living systems legible to capital without flattening what makes them alive. BlueDot Project is the small firm testing whether that bridge can carry real weight.
The Quiet Fund That Turned Tennessee Into a Startup State
For more than a decade, a small Nashville nonprofit has been doing the unglamorous work of turning Tennessee ideas into fundable companies. Here is how LaunchTN built a statewide engine out of capital, connections, and commercialization.
InvestorFlow
InvestorFlow is a San Francisco-based software company that builds a purpose-built CRM and investor portal for private markets firms - private equity, private credit and real assets managers. Built on Salesforce and layered with AI, its platform unifies fundraising (capital formation), deal sourcing and execution (capital deployment), and LP engagement and reporting (investor services) in one place. Formed through the 2022 merger of InvestorFlow's investor portal with the Blackstone-incubated FundEngine CRM (Cloud Theory) and backed by a $30M Series A from Ambina Partners, the company serves more than 200 alternative asset managers - including 25 of the top 50 - representing over $6 trillion in assets, 750 funds and 90,000 LPs.
Aditya Venugopal
Aditya Venugopal is the Chief Business Officer of Alentis Therapeutics, a clinical-stage Swiss biotech chasing first-in-class therapies aimed at claudin-1 for fibrosis and cancer. An immunologist turned dealmaker, he spent 15-plus years moving between the lab bench and the negotiating table: a Ph.D. in immunology from Weill Cornell, seven years in strategic life-science consulting, then senior roles at Intercept, VectivBio and Versanis Bio. He has a habit of being in the room when companies get acquired - VectivBio went to Ironwood, Versanis went to Eli Lilly - and he reunited with CEO Mark Pruzanski at Alentis after first partnering with him at Intercept.
Tom Morgan
Thomas W. Morgan is a 30-year private equity veteran who pioneered the GP stakes investing category when he founded Hycroft Capital in 2015, the first firm dedicated solely to minority, non-control investments in private equity management companies. His career arc spans First Boston, Bain Capital during its formative 1990s growth, and 15 years at New Mountain Capital (raising $15B+ AUM). After merging Hycroft into Magnetar Capital and co-founding Aviditi Advisors (acquired by Piper Sandler in 2024), he now manages Greylock Capital Partners, his family office with interests in franchise concepts, commercial real estate, and private investments, from Manhattan's Upper East Side.